Faculty of pharmacy department of human pharmacology and toxicology

Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591.

Andrews RC, Walker BR. (1999). Glucocorticoids and insulin resistance: Old hormones, new targets. Clinical Science, 96:513-523.

Aronne LJ, Segal KR. (2003). Weight gain in the treatment of mood disorders. Journal of Clinical Psychiatry, 64(8):22–9.

Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, et al. (2004). Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. Journal Clinical Psychiatry, 65(10):1335-42.

Ashton, C.H., Moore, P.B., 2011. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr. Scand. 124 (4), 250–261.

Atlantis E, Baker M. (2008). Obesity effects on depression: a systematic review of epidemiological studies. International Journal of Obesity, 32(6):881-91.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology. 2002;46:67–9.

Balt SL, Galloway GP, Baggott MJ, Schwartz Z, Mendelson J. Mechanisms and genetics of antipsychotic-associated weight gain. Clinical Pharmacology Therapy, 90(1):179-183.

Barry D, Pietrzak RH, Petry NM. (2008). Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Annals of Epidemiology, 18:458-466.

Bell, C.G., Walley, A.J., Froguel, P. (2005). The genetics of human obesity. National Review of Genetics, 6(3):221–234.

Bermudez-Silva, F.J., Cardinal, P., Cota, D., 2012. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. Journal of Psychopharmacology, 26(1):114–124.

Bonaccorso S, Sodhib M, Lic J, Bobod W.V, Chene Y, Tumukluf M, Theleritisa C, Jayathilakec K and Meltzer H.Y. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia (2015).

Online retrieved from: https://www.researchgate.net/publication/275046651

Bond, D.J., Lang, D.J., Noronha, M.M., et al. (2011). The association of elevated body mass index with reduced brain volumes in first-episode mania. Biology Psychiatry, 70(4):381–387.

Brabant C, Alleva L, Quertemont E, Tirelli E. Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence. Prog Neurobiol. 2010;92:421-41.

Bradshaw T., Mairs H. (2014). Obesity and Serious Mental Ill Health: A Critical Review of the Literature. Healthcare, 2(2):166-182.

Brandacher G, Hoeller E, Fuchs D,Weiss HG. Chronic immune activation underliesmorbid obesity: is IDO a key player? Curr Drug Metab 2007;8(3):289–95.

Brandacher, G. et al. 2006. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obes. Surg. 16: 541–548.

Britvic, D., Maric, N.P., Doknic, M., Pekic, S., Andric, S., Jasovic-Gasic, M., Popovic, V. (2013). Metabolic issues in psychotic disorders with the focus on first-episode patients: a review. Psychiatry Danub, 25:410–415.

Brown ES, Varghese FP, McEwen BS. (2004). Association of depression with medical illness: Does cortisol play a role? Biological Psychiatry, 55:1-9.

Carpenter KM, Hasin DS, Allison DB, Faith MS. (2000). Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicidal attempts: results from a general population survey. American Journal of Public Health, 90(2):251-7.

Carr C.P., Martins, C.M., Stingel, A.M., Lemgruber, V.B., Juruena, M.F. (2013). The role of early life stress in adult psychiatric disorders: a systematic review according to childhood trauma subtypes. Journal of Nerv. Mental Disorder, 201(12):1007–1020.

Carr D, Friedman MA (2005). Is obesity stigmatizing? Body weight perceived discrimination and psychological well-being in the United States. Journal of Health and Social Behavior, 46(3):244-259.

Cervantes, P., Gelber, S., Kin, F.N., Nair, V.N., Schwartz, G. (2001). Circadian secretion of cortisol in bipolar disorder. Journal Psychiatry Neuroscience, 26(5):411–416.

Chaouloff F, Gunn SH, Young JB. Central 5-hydroxytryptamine2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist d-fenfluramine in the conscious rat.(1992) J Pharmacol Exp Ther.;260:1008–16.

Charmandari E, Kino T, Souvatzoglou E, Chrousos GP. (2003). Pediatric stress: hormonal mediators and human development. Hormonal Research, 59(4):161-79.

Chen Y, Jiang Y, Mao Y. (2009). Association between obesity and depression in Canadians. Journal of Women's Health, 18(10):1687-92.

Chengappa KN, Chalasani L, Brar JS, Parepally H. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther. 2002;24:1576–84.

Choi, J., Joseph, L., Pilote, L. (2013). Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obesity Review, 14(3), 232–244.

Chokka P, Tancer M, Yeragani VK. (2006). Metabolic syndrome: relevance to antidepressant treatment. Journal of Psychiatry Neuroscience, 31:414.

Christopoulou, F.D., Kiortsis, D.N., 2011. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1receptor blockers in obesity. J. Clin. Pharm. Ther. 36 (1), 10–18.

Cindik N, Baskin E, Agras PI, Kinik ST, Turan M, Saatci U. (2005). Effect of obesity on inflammatory markers and renal functions. Acta Paediatrics, 94(12):1732-7.

Cole, J.H., Boyle, C.P., Simmons, A., et al. (2013). Body mass index, but not FTO genotype or major depressive disorder, influences brain structure. Neuroscience, 252:109–117.

Collins, J., Bentz, J (2009). Behavioral And Psychological Factors In Obesity. The Journal of Lancaster General Hospital, 124(4).

Corman CL, Leung NM, Guberman AH. (1997). Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Canadian Journal of Neurol Science, 24:240-244.

Correll CU, Lencz T, Malhotra AK. (2011). Antipsychotic drugs and obesity. Trends of Molecular Medicine, 17:97-107.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302:1765–1773.

Correll, C.U., Lencz, T., Malhotra, A.K. (2011). Antipsychotic drugs and obesity. Trends in Molecular Medicine, 17(2), 97–107.

Daban, C., Vieta, E., Mackin, P., Young, A.H. (2005). Hypothalamic–pituitary–adrenalaxis and bipolar disorder. Psychiatric Clinical Am, 28 2):469–480.

Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. (2004). Three-year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry, 4:16.

Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, et al. (2007). A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacology, 30:326–34.

Deng C, Weston-Green K, Huang X, et al.(2010), The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain? Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34:1-4.

De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. (2006). Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research, 83:87–93.

de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruano G, et al. (2007). A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Research, 92:95–102.

de Wit L, Luppino F, van Straten A et al. (2010). Depression and obesity: a meta-analysis of community-based studies. Psychiatry Research, 178:230–235.

Dent R, Blackmore A, Peterson J, Habib R, Kay GP, Gervais A, et al. (2012). Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One, 7:36889.

Derijks HJ, Meyboom RH, Heerdink ER, De Koning FH, Janknegt R, Lindquist M, et al. (2008a) The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol.;64: 531–8.

Derijks HJ, Heerdink ER, De Koning FH, Janknegt R, Klungel OH, Egberts AC.(2008b) The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study. Pharmacoepidemiol Drug Saf.;17:336–44.

Desai, R. A., Manley, M., Desai, M. M., & Potenza, M. N. (2009). Gender differences in the association between body mass index and psychopathology. CNS Spectrums, 14(7), 372–383.

Devaux, M., Sassi, F. (2013). Social inequalities in obesity and overweight in 11 OECD countries. European Journal of Public Health, 23(3):464–469.

Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. (2007). Variation in FTO contributes to childhood obesity and severe adult obesity. Nationa Genetics, 39:724-726.

Dossenbach M, Treuer T, Kryzhanovskaya L, Saylan M, Dominguez S, Huang X, et al. Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa. J Clin Psychopharmacol. 2007;27(4):329–37.

Dotsch J, Rascher W, Meissner U. (2005). New insights into leptin resistance by modifying cytokine receptor signal transduction. European journal of endocrinology/European Federation of Endocrine Societies, 152:333-334.

Dowlati, Y., Herrmann, N., Swardfager, W., et al. (2010). A meta-analysis of cytokines in major depression. Biology Psychiatry, 67(5):446–457.

Duncan , Nakia A. Clifford, Kalin M. Shvarts, Olga M 2015 . Mirtazapine-Associated Hypertriglyceridemia and Hyperglycemia. American Society of Consultant Pharmacists, 30 (11): 657-663

Eker ÖD., Eker M.C. (2010). Metabolic Side Effects of Lithium. Current Approaches in psychiatry, 2(1):2651.

Elmquist JK, Bjørbæk C, Ahima R.S., Flier JS, Saper CB. (1998). Distributions of leptin receptor mRNA isoforms in the rat brain, Journal of Comparative Neurology, 395(4):535–547.

Everson, S.A., Maty, S.C., Lynch, J.W., Kaplan, G.A. (2002). Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. Journal of Psychosom Research, 53(4):891–895.

Faith MS, Matz PE, Jorge MA. (2002). Obesity-depression associations in the population. Journal of Psychosomatic Research, 53:935-42

Farmer A, Korszun A, Owen MJ, Craddock N, Jones L, Jones I, et al. (2008). Medical disorders in people with recurrent depression. British Journal of Psychiatry, 192:351-355.

Fava M. Weight gain and anti depressants (2000) J Clin Psychiatry. 61 Suppl 11:37–41.

Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863–7.

Fernandez-Egea, E., Bernardo, M., Donner, T., Conget, I., Parellada, E., Justicia, A., Esmatjes, E., Garcia-Rizo, C., Kirkpatrick, B. (2009). Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Britsh Journal of Psychiatry, 194:434–438.

Ferrannini E, Haffner SM, Mitchell BD, Stern MP. (1991). Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia, 34:416-22.

Ferrante AW Jr. (2007). Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. Journal of Internation Medicine, 262(4):408-14.

Foley, D. Morley, K.I. (2011). A systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch. Gen. Psychiatry, 68:609-616.

Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. (2007). A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science, 316:889-894.

Finkelstein, J.A. 1982. Brain serotonergic activity and plasma amino acid levels in genetically obese Zucker rats. Pharmacol. Biochem. Behav. 17: 939–944.

Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine induced weight gain. Am J Psychiatry. 2003; 160:797.

Fukui H, Murai T. Severe weight gain induced by combination treatment with risperidone and paroxetine. Clin Neuropharmacol. 2002;25(5):269–71

Garcia-Garcia, I., Jurado, M.A., Garolera, M et al. (2012). Functional connectivity in obesity during reward processing. Neuroimage, 66C:232–239.

Gariepy G, Nitka D, Schmitz N. (2010). The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. International Journal of Obesity, 34:407-19.

Garland EJ, Remick RA, Zis AP. (1988). Weight gain with antidepressants and lithium. Journal of Clinical Psychopharmacology, 8(5):323-30.

Gavin AR, Rue T, Takeuchi D. (2010). Racial/Ethnic Differences in the Association Between Obesity and Major Depressive Disorder: Findings from the Comprehensive Psychiatric Epidemiology Surveys. Public Health Reports, 125(5):698-708.

Gold PW, Chrousos GP. (2002). Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Molecular Psychiatry, 7(3):254-75.

Gotlib IH, Joormann J, Minor KL, Hallmayer J. (2008). HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression. Biology Psychiatry, 63(9):847-51.

Gragnoli C. Hypothesis of the neuroendocrine cortisol pathway gene role in the comorbidity of depression, type 2 diabetes, and metabolic syndrome. The Application of Clinical Genetics 2014; 7:43-53

Gracious B.L and Meyer A.E. (2005). Psychotropic-Induced Weight Gain and Potential Pharmacologic Treatment Strategies. Psychiatry; 2(1): 36–42.

Weston-Green K, Huang XF, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol. 2012 ;22(5):364-73.

Guest, P.C., Schwarz, E., Krishnamurthy, D., Harris, L.W., Leweke, F.M., et al. (2011). Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology, 36:1092–1096.

Guest, P.C., Wang, L., Harris, L.W., Burling, K., Levin, Y., et al. (2010). Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïveschizophrenia patients. Molecular Psychiatry, 15:118–119.

Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88:1183-241.

Harris L.W., Guest P.C., Wayland M.T., Umrania Y., Krishnamurthy D., Rahmoune H., Bahn S., (2013). Schizophrenia: metabolic aspects of aetiology, diagnosis, and future treatment strategies. Psychoneuroendocrinology, 38:752–766.

Harvey B, Bouwer C. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol. 2000;23:90–7.

Hayashi A, Sonoda R, Kimura Y et al., Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Research, 1011(2):221–227, 2004.

Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. (2004). Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA, 16; 291(23):2847-50.

Hickman, R.J., Khambaty, T., Stewart, J.C. (2013). C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Journal of Behavioral Medicine, 37(4):621-9.

Hill, M.N., Tasker, J.G., 2012. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic–pituitary–adrenal axis.Neuroscience 20(4), 5–16.

Himmerich, Hubertus; Minkwitz, Juliane; C. Kirkby, Kenneth., (2015). Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),15(4),: 252-260.

Hinze-Selch D, Schuld A, Kraus T, Kühn M, Uhr M, Haack M, Pollmächer T. (2000). Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha, and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology, 23(1):13-9.

Holt RIG, Peveler RC, Byrne CD. (2004). Schizophrenia, the metabolic syndrome, and diabetes. Diabetes Medicine, 21(6):515-23.

Howren, M.B., Lamkin, D.M., Suls, J. (2009). Associations of depression with C-reactive protein IL-1, and IL-6: a meta-analysis. Psychosom Medicine, 71(2):171–186.

Isaac R, Boura-Halfon S, Gurevitch D, Shainskaya A, Levkovitz Y, Zick Y. Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β-cells. J Biol Chem. 2013;288:5682–93.

Iwasaki Y, Takayasu S, Nishiyama M, Tsugita M, Taguchi T, Asai M, et al. (2008). Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene. Molecular Cell Endocrinology, 285:10-8.

Johnson, D. E., Yamazaki, H., Ward, K. M., Schmidt, A. W., Lebel, W. S., Treadway, J. L., et al. (2005). Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic induced diabetes and hyperglycemia. Diabetes 54, 1552−1558.

Jones, A., McMillan, M.R., Jones, R.W., et al. (2012). Adiposity is associated with blunted cardiovascular, neuroendocrine and cognitive responses to acute mental stress. PLoS ONE, 7(6):e39143.

Kendler, K.S., Gatz, M., Gardner, C.O., Pedersen, N.L., 2006. A Swedish national twin study of lifetime major depression. American Journal of Psychiatry, 163(1):109–114.

Kerner, B. (2014). Genetics of bipolar disorder. Applied Clinical Genetics, 7:33–42.

Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm. 2011;33:484–92.

Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. (2007). Cytokine imbalance in the pathophysiology of the major depressive disorder. Programme of Neuropsychopharmacol Biol Psychiatry, 31(5):1044-53.

Kivimaki M, Batty G, Singh-Manoux A, Nabi H, Sabia S, Tabak AG, et al. (2009). Association between common mental disorder and obesity over the adult life course. British Journal of Psychiatry 2009;195(2):149-55.

Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM, et al. (2007). Clozapine and olanzapine are associated with food craving and binge eating: Results from a randomized double-blind study. Journal of Clinical Psychopharmacology, 27, 662–666.

Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T. (2002). Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 35:220-225.

Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T. (2002). Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 35(6):220-5.

Krubde H, Birbrmann, Luck W, hon R, Brabant G, Grutes A. (1998). Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. National Genetics, 19:155-7

Kubera, B., Hubold, C., Zug, S., et al. (2012). The brain’s supply and demand in obesity. Front Neuroenergetics 4:4.

Lai, J.S., Hiles, S., Bisquera, A., Hure, A.J., McEvoy, M., Attia, J. (2014). A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. American Journal of Clinical Nutrition, 99(1):181–197

Lamers, F., Vogelzangs, N., Merikangas, K.R., de Jonge, P., Beekman, A.T., Penninx, B.W. (2013). Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Molecular Psychiatry, 18(6):692–699.

Lamertz CM, Jacobi C, Yassouridis A, Arnold K, Henkel AW. (2002). Are obese adolescents and young adults at higher risk for mental disorders? A community survey. Obesity Research, 10(11):1152-60.

Lee NY, Kim SH, Cho B, Lee YJ, Chang JS, Kang UG, Kim YS, Ahn YM. (2010). Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. Prog Neuropsychopharmacol Biol Psychiatry, 34(7):1243-9.

Lee, C., Tsenkova, V., Carr, D. (2014a). Childhood trauma and metabolic syndrome in men and women. Social Science Medicine, 105:122–130.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373:31–41.

Levkovitz Y, Ben-Shushan G, Hershkovitz A, Isaac R, Gil-Ad I, Shvartsman D, et al. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases.(2007) Mol Cell Neurosci.;36:305–12.

Liao, Y., Huang, X., Wu, Q et al. (2013). Is depression a disconnection syndrome?Meta-analysis of diffusion tensor imaging studies in patients with MDD. Journal Psychiatry Neuroscience, 38(1):49–56.

Lieberman JA, et al. (2009). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353:1209–23

Loos RJ, Bouchard C. (2008). FTO: the first gene contributing to common forms of human obesity. Obesity Review, 9:246-250.

Loos RJ, Bouchard C. Obesity-is it a genetic disorder? Journal of International Medicine, 254:401-25.

Lopresti, A.L., Hood, S.D., Drummond, P.D. (2013a). A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep, and exercise. Journal of Affective Disorder, 148(1):12–27.

Lopresti A, Drummond P. (2013b) Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 45:92-99.

Luppino FS, de Wit LM, Bouvy PF et al. (2010). Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry, 67:220–229.

Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH, et al. (2010). Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Archives of General Psychiatry, 67(3):220-9.

Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23:618–23.